^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
INB-300
i
Other names: INB-300, DeltEx DRI CAR-T, DeltEx chlorotoxin-CAR-gamma-delta-T cells, chlorotoxin/methylguanine-DNA methyltransferase (MGMT) γδ-T cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
IN8bio
Drug class:
γδ TCR modulator, CLTX-targeted CAR-T immunotherapy
Related drugs:
3years
[VIRTUAL] Dual chlorotoxin and methylguanine methyltransferase γδ-T cells for drug resistant immunotherapy of glioblastoma multiforme (AACR 2021)
We have developed a novel approach to the treatment of primary GBM by combining simultaneous intracranial administration of gene-modified γδ T cells and standard temozolomide (TMZ) maintenance chemotherapy. Overall, we were able to generate dCLTX-CAR T cells with resistance to TMZ and showed improved activation and cytotoxicity against GBM cells under TMZ exposure. Our approach of combining the dCLTX-CAR and TMZ resistance will be further validated in animal model experiments and could be a potential candidate for clinical development for GBM.
IO biomarker
|
MGMT (6-O-methylguanine-DNA methyltransferase) • CD69 (CD69 Molecule) • MMP2 (Matrix metallopeptidase 2)
|
temozolomide • INB-300
Share via
